High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study

Radiation Oncology

Yan Chen¹  Ya-Jun Ku¹  Yu Peng¹  Jie Zong¹  Na Wang¹  Bin Cao¹  Xiao-Cang Ren¹  Xue-Ji Chen¹  Fan-Jie Meng¹  Qiang Lin¹  Yue-E Liu¹ 

[1] Department of Oncology, North China Petroleum Bureau General Hospital of Hebei Medical University, 8 Huizhan Avenue, Renqiu, Hebei Province 062552, P.R. China

关键词: Carboplatin;    Vinorelbine;    Three-dimensional conformal radiotherapy;    Concurrent chemoradiotherapy;    Accelerated hypofractionated radiotherapy;    Non-small-cell lung cancer;   

Others  :  1153220
DOI  :  10.1186/1748-717X-8-198

 received in 2013-05-05, accepted in 2013-08-02,  发布年份 2013

【 摘 要 】

Background

Increasing the radiotherapy dose can result in improved local control for non-small-cell lung cancer (NSCLC) and can thereby improve survival. Accelerated hypofractionated radiotherapy can expose tumors to a high dose of radiation in a short period of time, but the optimal treatment regimen remains unclear. The purpose of this study was to evaluate the feasibility of utilizing high-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for the treatment of local advanced NSCLC.

Methods

Untreated patients with unresectable stage IIIA/IIIB NSCLC or patients with a recurrence of NSCLC received accelerated hypofractionated three-dimensional conformal radiotherapy. The total dose was greater than or equal to 60 Gy. The accelerated hypofractionated radiotherapy was conducted once daily at 3 Gy/fraction with 5 fractions per week, and the radiotherapy was completed in 5 weeks. In addition to radiotherapy, the patients also received at least 1 cycle of a concurrent two-drug chemotherapy regimen of NVB and CBP.

Results

A total of 26 patients (19 previously untreated cases and 7 cases of recurrent disease) received 60Gy-75Gy radiotherapy with concurrent chemotherapy. All of the patients underwent evaluations for toxicity and preliminary therapeutic efficacy. There were no treatment-related deaths within the entire patient group. The major acute adverse reactions were radiation esophagitis (88.5%) and radiation pneumonitis (42.3%). The percentages of grade III acute radiation esophagitis and grade III radiation pneumonitis were 15.4% and 7.7%, respectively. Hematological toxicities were common and did not significantly affect the implementation of chemoradiotherapy after supportive treatment. Two patients received high dose of 75 Gy had grade III late esophageal toxicity, and none had grade IV and above. Grade III and above late lung toxicity did not occur.

Conclusion

High-dose accelerated hypofractionated three-dimensional conformal radiotherapy with a dose of 60 Gy or greater with concurrent NVB and CBP chemotherapy might be feasible. However esophagus toxicity needs special attention. A phase I trial is recommended to obtain the maximum tolerated radiation dose of accelerated hypofractionated radiotherapy with concurrent chemotherapy.

【 授权许可】

   
2013 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Stinchcombe TE, Bogart JA: Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist 2012, 17:682-693.
• [2]Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR: Improved survival in stage III non-small-cell lung cancer: seven year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996, 88:1210-1215.
• [3]Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2181-90.
• [4]Bradley JD, Moughan J, Graham MV, Byhardt R, Govindan R, Fowler J, Purdy JA, Michalski JM, Gore E, Choy H: A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 2010, 77:367-372.
• [5]Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, Garces YI, Shahidi H, Tschetter LK, Schaefer PL, Adjei A, Jett J: Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 65:1106-1111.
• [6]Bradley JD, Paulus R, Komaki R: A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy cetuximab for stage IIIa/IIIb non-small cell lung cancer: Preliminary findings on radiation dose in RTOG 0617. Miami Beach, Florida: Presented at the 53rd ASTRO Annual Meeting; 2011.
• [7]Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J: A new approach to dose escalation in non–small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001, 49:23-33.
• [8]Salama JK, Vokes EE: New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol 2013, 31:1029-1038.
• [9]Uitterhoeve AL, Belderbos JS, Koolen MG, van der Vaart PJ, Rodrigus PT, Benraadt J, Koning CC, González González D, Bartelink H: Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: Results of the EORTC 08912 phase I/II study: European Organization for Research and Treatment of Cancer. Eur J Cancer 2000, 36:592-600.
• [10]Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, Price A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, Koning C, EORTC LCG and RT Group: Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972–22973). Eur J Cancer 2007, 43:114-121.
• [11]Maguire J, McMenemin R, O’Rourke N: SOCCAR: sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC. J Clin Oncol 2011, 29:462s. suppl; abstr 7039
• [12]Carruthers R, O'Rourke N, Mohammed N, Hicks J, Brisbane : Toxicity of hypofractionated accelerated radiotherapy concurrent with chemotherapy for non-small cell carcinoma of the lung. Clin Oncol (R Coll Radiol) 2011, 23:561-562.
• [13]Cho KH, Ahn SJ, Pyo HR, Kim KS, Kim YC, Moon SH, Han JY, Kim HT, Koom WS, Lee JS: A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study. Int J Radiat Oncol Biol Phys 2009, 74:1397-1404.
• [14]Osti MF, Agolli L, Valeriani M, Falco T, Bracci S, De Sanctis V, Enrici RM: Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013, 85(3):e157-163.
• [15]Xie SX, Li WX, Lin YR, Zou WC: Three-dimensional conformal hypofractionated radiotherapy for non-small –cell lung cancer. China Oncology 2006, 12:1034-1037. in Chinese
• [16]Kim B, Ahn YC, Lim do H, Nam HR: High-dose thoracic radiation therapy at 3.0 Gy/fraction in inoperable stage I/II non-small cell lung cancer. Jpn J Clin Oncol 2008, 38:92-98.
• [17]Xie SX, Li WX, Zeng ZJ, Chen YR: Escalated dose trial with hypofractionated three-dimensional conformal radiation therapy for non-small cell lung cancer. Chin J Clin Oncol 2009, 36:972-975. (in Chinese)
• [18]Zhu GY, Xia TY, Wang LH, Gao XS, Wang JJ, Li GF, Zhang FQ, Ma L, Li YX, Xu B: Consensus and controversies on delineation of radiotherapy target volume for patients with non-small cell lung cancer. Chin J Radiat Oncol 2008, 17:432-436. (in Chinese)
• [19]Lin Q, Liu Y, Wang N, Huang Y, Ge X, Ren X, Chen X, Hu J, Guo Z, Zhao Y, Asaumi J: A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer. J Radiat Res 2013, 54:126-134.
• [20]Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
• [21]Beli I, Koukourakis G, Platoni K, Tolia M, Kelekis N, Kouvaris J, Syrigos C, Mystakidou K, Varveris C, Kouloulias V: Hypofractionated radiotherapy in non small cell lung cancer: a review of the current literature. Rev Recent Clin Trials 2010, 5:103-111.
• [22]Fowler JF, Chappell R: Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 2000, 46:516-517.
• [23]Fletcher GH: Clinical dose response curves of human malignant epithelial tumors. Br J Radiol 1973, 46:151.
• [24]Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, Kalemkerian GP, Hayman JA: High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005, 63:324-333.
• [25]Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2(7 Suppl 3):S94-100.
• [26]Thirion P, Holmberg O, Collins CD, O'Shea C, Moriarty M, Pomeroy M, O'Sullivan C, Buckney S, Armstrong J: Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol 2004, 71:163-166.
• [27]Ohri N, Dicker AP, Lawrence YR: Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. Int J Radiat Oncol Biol Phys 2012, 83:385-393.
• [28]Zhu ZF, Fan M, Wu KL, Zhao KL, Yang HJ, Chen GY, Jiang GL, Wang LJ, Zhao S, Fu XL: A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. Radiother Oncol 2011, 98:304-308.
• [29]Glynne-Jones R, Sebag-Montefiore D: Chemoradiation schedules–what radiotherapy? Eur J Cancer 2002, 38:258-269.
• [30]Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
• [31]Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004, 46:87-98.
• [32]Lin Q, Wang J, Liu Y, Su H, Wang N, Huang Y, Liu CX, Zhang P, Zhao Y, Chen K: High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: a feasibility study. Oncol Lett 2011, 2(4):669-674.
• [33]Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103:1452-1460.
• [34]Fournel P, Robinet G, Thomas P, Souquet PJ, Léna H, Vergnenégre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daurés JP, Mornex F, Pérol M: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95–01 study. J Clin Oncol 2005, 23:5910-5917.
• [35]Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper A, Green M, Miller AA, Vokes EE: Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008, 26:2457-2463.
• [36]Harada H, Nishio M, Murakami H, Ohyanagi F, Kozuka T, Ishikura S, Naito T, Kaira K, Takahashi T, Horiike A, Nishimura T, Yamamoto N: Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent s-1 and cisplatin for inoperable stage iii non-small-cell lung cancer. Clin Lung Cancer 2013, 14:440-445.
• [37]Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial: CHART Steering Committee. Lancet 1997, 350:161-165.
• [38]Belderbos J, Heemsbergen W, Hoogeman M, Pengel K, Rossi M, Lebesque J: Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol 2005, 75:157-164.
• [39]Bradley J, Deasy JO, Bentzen S, El Naqa I: Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 2004, 58:1106-1113.
• [40]Singh AK, Lockett MA, Bradley JD: Predictors of radiationinduced esophageal toxicity in patients with nonsmall-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003, 55:337-341.
• [41]Maguire PD, Sibley GS, Zhou SM, Jamieson TA, Light KL, Antoine PA, Herndon JE 2nd, Anscher MS, Marks LB: Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 1999, 45:97-103.
• [42]Werner-Wasik M, Pequignot E, Leeper D, Hauck W, Curran W Jr: Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariable analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 2000, 48:689-696.
• [43]van Baardwijk A, Bosmans G, Boersma L, Wanders S, Dekker A, Dingemans AM, Bootsma G, Geraedts W, Pitz C, Simons J, Lambin P, De Ruysscher D: Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys 2008, 71:1394-1401.